title: Do teleoncology models of care enable safe delivery of chemotherapy in rural towns?
abstract: OBJECTIVE
  To compare the dose intensity and toxicity profiles for patients undergoing chemotherapy at the Townsville Cancer Centre (TCC), a tertiary cancer centre in northern Queensland, with those for patients treated in Mount Isa, supervised by the same medical oncologists via teleoncology.
  
  
  METHODS
  A quasi-experimental design comparing two patient groups.
  
  
  METHODS
  TCC and Mount Isa Hospital, which both operate under the auspices of the Townsville Teleoncology Network (TTN).
  
  
  METHODS
  Eligible patients who received chemotherapy at TCC or Mt Isa Hospital between 1 May 2007 and 30 April 2012.
  
  
  METHODS
  Teleoncology model for managing cancer patients in rural towns.
  
  
  METHODS
  Dose intensity (doses, number of cycles and lines of treatment) and toxicity rates (rate of serious side effects, hospital admissions and mortality).
  
  
  RESULTS
  Over 5 years, 89 patients received a total of 626 cycles of various chemotherapy regimens in Mount Isa. During the same period, 117 patients who received a total of 799 cycles of chemotherapy at TCC were eligible for inclusion in the comparison group. There were no significant differences between the Mount Isa and TCC patients in most demographic characteristics, mean numbers of treatment cycles, dose intensities, proportions of side effects, and hospital admissions. There were no toxicity-related deaths in either group.
  
  
  CONCLUSIONS
  It appears safe to administer chemotherapy in rural towns under the supervision of medical oncologists from larger centres via teleoncology, provided that rural health care resources and governance arrangements are adequate.
authors.affiliation: Townsville Cancer Centre, Townsville, QLD Sabe.sabesan@health.qld.gov.au.
authors.forename: Bryan A
authors.initials: BA
authors.lastname: Chan
authors.affiliation: Anton Breinl Research Centre for Health Systems Strengthening, James Cook University, Townsville, QLD.
authors.forename: Sarah L
authors.initials: SL
authors.lastname: Larkins
authors.affiliation: Anton Breinl Research Centre for Health Systems Strengthening, James Cook University, Townsville, QLD.
authors.forename: Rebecca
authors.initials: R
authors.lastname: Evans
authors.affiliation: James Cook University, Townsville, QLD.
authors.forename: Kerrianne
authors.initials: K
authors.lastname: Watt
authors.affiliation: Townsville Cancer Centre, Townsville, QLD.
authors.forename: Sabe
authors.initials: S
authors.lastname: Sabesan
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008297:Male; D008495:Medical Oncology / Q000379:methods; D008875:Middle Aged; D017146:Models, Organizational; D009369:Neoplasms / Q000453:epidemiology / Q000628:therapy*; D016522:Oncology Service, Hospital / Q000458:organization & administration*; D011793:Queensland; D012189:Retrospective Studies; D019035:Rural Health Services / Q000458:organization & administration*; D012424:Rural Population / Q000706:statistics & numerical data; D017216:Telemedicine / Q000458:organization & administration*; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents